No way! But... [Design Issues]

posted by wienui  – Germany, Oman, 2019-12-07 04:01  – Posting: # 20955
Views: 1,044

(edited by wienui on 2019-12-07 06:47)

Dear all,

» So here two answers - theoretically there is no problem to use all data, but regulatory authorities can bann you for it. (IMHO)

I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

Best regards,


Complete thread:

 Admin contact
20,250 posts in 4,262 threads, 1,398 registered users;
online 23 (0 registered, 23 guests [including 14 identified bots]).
Forum time (Europe/Vienna): 07:21 CET

No written law has ever been more binding than
unwritten custom supported by popular opinion.    Carrie Chapman Catt

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz